Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-finding study of oral TNO155 ± nazartinib in advanced solid tumors
jRCT2080224175Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of batoprotafib in Nonhematologic neoplasms (2 arms), sponsored by Novartis. Primary endpoint: Dose-limiting toxicities (DLTs) and recommended dose determination. Started Dec 2018; status: completed.
02
Drugs
batoprotafib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224175.